ViiV Healthcare: ViiV Healthcare showcases leadership in longacting injectables innovation at CROI 2025 with data on thirdgeneration integrase inhibitor and highly potent capsid inhibitor against HIV1

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced positive findings from two phase IIa proof─of─concept studies of investigational antiretroviral therapies